For research use only. Not for therapeutic Use.
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer[1].
Sontuzumab (huHMFG-1; 0-25 μg/mL) induces antibody-dependent cellular cytotoxicity (ADCC) in the breast tumor cell line ZR-75-1, in three bone marrow-derived tumor cell lines from breast cancer patients (KM22, 1590, HG15), and in Chinese hamster ovary (CHO) cells transfected with the human MUC1 gene, by using peripheral blood mononuclear cells (PBMCs) from healthy donors. Cell lines that do not express human MUC1 are not susceptible to ADCC in the presence of Sontuzumab[1][2].
| Catalog Number | I041608 |
| CAS Number | 372075-37-1 |
| Purity | ≥95% |
| Reference | [1]. Pegram MD, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73. [2]. Snijdewint FG, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer. 2001 Jul 1;93(1):97-106. |
